Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / NID2

NID2

Basics

Aliases:
This biomarker is also known as:
  • nidogen 2 (osteonidogen),
  • NID-2,
  • nidogen-2,
  • osteonidogen,
  • Osteonidogen,

View in BioMuta

Description…

NID2 is a member of the nidogen family of basement membrane proteins. It is a cell adhesion glycoprotein that binds collagens I and IV and laminin. NID2 may be involved in maintaining the structure of the basement membrane, and in cell-extracellular matrix interactions.

Attributes

QA State: Curated
Type: Gene
Short Name:
HGNC Name: NID2

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Head & neck, NOS

Attributes

Phase: One
QA State: Curated

Overview

HOXA9 and NID2 have been identified as novel differentially methylated genes in oral squamous cell carcinoma. These genes were also shown to have significantly higher methylation levels in tumor than normal oral mucosa, as seen by ROC analysis of head and neck squamous cell carcinoma samples.

Performance Comment

HOXA9 and NID2 are promising oral squamous cell carcinoma biomarkers that should be studied on tissue, saliva and serum from larger cohorts.  HOXA9 and NID2 were chosen for further study because they were the only candidate genes that had an AUC value equal to or higher than 0.75,  and 100% specificity and sensitivity higher than 70%.

Ovary

Attributes

Phase: One
QA State: Under Review

Overview

NID2 is a biomarker for ovarian cancer which correlates closely with CA125. NID2 was elevated in serum of patients with ovarian carcinoma, compared to patients with benign gynecological diseases and normal controls.

Performance Comment

NID2 is a biomarker for ovarian cancer which correlates closely with CA125. NID2 was elevated in serum of patients with ovarian carcinoma, compared to patients with benign gynecological diseases and normal controls.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.